The bioresorbable medical material market has seen considerable growth due to a variety of factors.
•The market size for bioresorbable medical materials has seen a significant expansion lately. There is a projected increase from $1.56 billion in 2024 to $1.72 billion in 2025, indicating a compound annual growth rate (CAGR) of 10.1%.
The noteworthy growth in the historic phase is due to the constrictions of customary non-resorbable materials, progress in polymer science, a rise in cardiovascular interventions, the growing elderly population, and the broadening of minimally invasive surgeries.
The bioresorbable medical material market is expected to maintain its strong growth trajectory in upcoming years.
• Anticipated to expand swiftly in the ensuing years, the bioresorbable medical material market is predicted to reach a value of $2.52 billion in 2029, alongside a 10.0% compound annual growth rate (CAGR).
Factors contributing to this surge during the forecasting period include a climbing demand for bioresorbable scaffolds, widespread incorporation of bioresorbable materials across varied medical applications, an increase in cardiovascular and orthopedic procedures, an enhanced emphasis on patient comfort and recovery, and widening application scope in tissue engineering. The forecast period also manifests notable trends including the personalization of bioresorbable materials for specific medical purposes, employment of bioresorbable materials within drug delivery systems, advancing 3d printing applications within the production of bioresorbable medical devices, the rise of combination products with bioresorbable components, and a focus on developing sustainable and environmentally friendly medical materials.
The rise in surgical operations is projected to drive the bioresorbable medical material market's expansion. Surgical processes, which involve cutting into the body and utilizing instruments to halt or mend diseases inside a living organism, are growing in number. Typically, bioresorbable polymers are employed in the manufacture of moulded medical devices used predominantly in neurology, orthopaedics, and cosmetic surgery. These materials can be utilized to produce things like sutures, anchors, and screws. For instance, as per the International Society of Aesthetic Plastic Surgery (ISAPS), a US-based institution, the count of aesthetic procedures approximated to nearly 35 million in 2023, with the total count of surgical and non-surgical procedures escalating by 3.4% to 34.9 million in June 2024. As a consequence, the accelerating number of surgical procedures is fuelling the expansion of the bioresorbable medical material market.
The bioresorbable medical material market covered in this report is segmented –
1) By Type: Polylactic Acid (PLA), Polyglycolic Acid (PGA), Polysaccharides, Polycaprolactone (PCL), Poly Lactic-Co-Glycolic Acid (PLGA)
2) By Application: Drug Delivery, Orthopedics, Other Applications
3) By End-User: Hospitals And Clinics, Ambulatory Surgical Centers, Research Institutes, Other End-Users
Subsegments:
1) By Polylactic Acid (PLA): Low Molecular Weight PLA, High Molecular Weight PLA, PLA Blends
2) By Polyglycolic Acid (PGA): Homopolymer PGA, Copolymer PGA
3) By Polysaccharides: Chitosan, Alginate, Hyaluronic Acid Derivatives
4) By Polycaprolactone (PCL): Standard PCL, PCL Copolymers
5) By Poly Lactic-Co-Glycolic Acid (PLGA): 50:50 PLGA, 75:25 PLGA, Other PLGA Ratios
A major trend emerging in the bioresorbable medical material market is the creation of innovative biomaterials. The major players in this market are making concerted efforts to develop such novel biomaterials, particularly for 3D printing applications, to maintain their market status. Zeus, a South Carolina-based firm known for its advanced polymer solutions spanning several industries including medical, aerospace, energy, automotive, and fiber optics, introduced a new generation of tubing for bioresorbable vascular scaffolds, named AbsorvTM XSE, in September 2023. This breakthrough enhances the performance of medical devices, notably in vascular treatments. AbsorvTM XSE represents a remarkable advancement in bioresorbable medical devices, with the potential to enhance patient outcomes and broaden treatment alternatives. The product impresses with its broad customizability, featuring a variety of polymer options and increased sizes to adjust mechanical and absorption characteristics. The improved wall thickness uniformity it offers enables more consistent production and around 25% more usable scaffolds after laser cutting compared to previous models.
Major companies operating in the bioresorbable medical material market include:
• Johnson & Johnson
• Abbott Laboratories
• Medtronic PLC
• Kureha Corporation
• Evonik Industries AG
• Stryker Corporation
• Toray Industries Inc.
• Mitsui Chemicals Inc.
• Arkema S.A.
• Royal DSM N.V.
• Zimmer Biomet Holdings Inc.
• Ashland Global Holdings Inc.
• Corbion N.V.
• Zeus Industrial Products Inc.
• Unitika Ltd.
• Danimer Scientific
• Synbra Technology
• KLS Martin Group
• Durect Corporation
• Putnam Plastics Corporation
• Zhejiang Haizheng Biomaterials Co. Ltd.
• NatureWorks LLC
• Foster Corporation
• Poly-Med Inc.
• Futerro S.A.
• TotalEnergies Corbion B.V.
North America was the largest region in the bioresorbable medical material market in 2024. Asia-Pacific is expected to be the fastest-growing region in the bioresorbable medical material market report during the forecast period. The regions covered in the bioresorbable medical material market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.